Dimenhydrinate
Dimenhydrinate is a small molecule pharmaceutical. Dimenhydrinate was first approved as Dimenhydrinate on 1982-01-01. It is used to treat motion sickness, nausea, vertigo, and vomiting in the USA.
Download report
Favorite
Top OTC Drugs
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
motion sickness | OTC monograph final | 2023-05-04 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
motion sickness | — | D009041 | T75.3 |
nausea | HP_0002018 | D009325 | R11.0 |
vertigo | — | D014717 | H81.39 |
vomiting | HP_0002013 | D014839 | R11.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
---|---|
J1240 | Injection, dimenhydrinate, up to 50 mg |
Clinical
Clinical Trials
18 clinical trials
View more details
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/trials-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Vertigo | D014717 | H81.39 | — | — | 1 | 2 | — | 3 | |
Vomiting | D014839 | HP_0002013 | R11.1 | — | — | — | 1 | 1 | 2 |
Nausea | D009325 | HP_0002018 | R11.0 | — | — | — | 1 | 1 | 2 |
Pain | D010146 | EFO_0003843 | R52 | — | — | — | 1 | — | 1 |
Postoperative pain | D010149 | G89.18 | — | — | — | 1 | — | 1 | |
Diabetes complications | D048909 | — | — | — | 1 | — | 1 | ||
Gastroenteritis | D005759 | EFO_1001463 | K52.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | 1 | — | — | 1 | 2 | |
Healthy volunteers/patients | — | 1 | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Radiodermatitis | D011855 | L58 | — | — | — | — | 1 | 1 | |
Dental implants | D015921 | — | — | — | — | 1 | 1 | ||
Retinal perforations | D012167 | EFO_1001028 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | DIMENHYDRINATE |
INN | dimenhydrinate |
Description | 8-chloro-1,3-dimethyl-7H-purine-2,6-dione 2-(diphenylmethyl)oxy-N,N-dimethylethanamine is a diarylmethane. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CN(C)CCOC(c1ccccc1)c1ccccc1.Cn1c(=O)c2[nH]c(Cl)nc2n(C)c1=O |
Identifiers
PDB | — |
CAS-ID | 523-87-5 |
RxCUI | 3444 |
ChEMBL ID | CHEMBL1200406 |
ChEBI ID | — |
PubChem CID | 10660 |
DrugBank | DB00985 |
UNII ID | JB937PER5C (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-terms-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,324 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-adverse-reactions-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
1,874 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more